Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals

A technology for medicine and rhinitis, applied in the application field of Biscarpamontamine A in the preparation of medicine for treating rhinitis, and can solve the problems of poor curative effect and ineffectiveness of rhinitis

Inactive Publication Date: 2016-03-02
ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, antihistamine drugs such as terfenadine or antiallergic drugs such as tranilast and ketotifen are mainly used in the treatment of rhinitis. These drugs have poor or ineffective effects on chronicity and recurrent rhinitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals
  • Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals
  • Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1: the preparation of compound BiscarpamontamineA tablet involved in the present invention:

[0016] Take 5 grams of compound Biscarpamontamine A, add 195 grams of dextrin, mix well, and make 1000 tablets by conventional compression.

Embodiment 2

[0017] Embodiment 2: the preparation of compound BiscarpamontamineA capsules involved in the present invention:

[0018] Get 5 grams of compound Biscarpamontamine A, add 180 grams of starch, mix well, pack into capsules and make 1000 capsules.

[0019] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0020] Experimental example 1, the influence of Biscarpamontamine A of the present invention on ovalbumin-induced allergic rhinitis in rats

[0021] Male SD rats, weighing 180-220 g, were intraperitoneally injected with 1 mg of ovalbumin and 10 mg of aluminum hydroxide gel, and then injected once every other day, a total of 7 times. From the 14th day, 10ul of 1mg / ml ovalbumin physiological saline solution was instilled into the nasal cavities of both sides of the rat every day, 7 times in total. Immediately after the last infusion, observe the number of times the rats sneeze and wipe their noses within 30 minutes, and the test drug is orally administered 1 hour before the last infusion of ovalbumin.

[0022] Table 1 Biscarpamontamine A of the present invention causes the influence (x ± SD) of rat allergic rhinitis to ovalbumin

[0023]

[0024] Compared with the control group, **P<0.01*P<0.05

[0025] It can be seen from Table 1 that Biscarpamontamine A (10, 20 mg / kg) sig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Biscarpamontamine A for treating immunity inflammation is used for preparing pharmaceuticals for treating immunity inflammation and particularly suitable for preparing pharmaceuticals for treating rhinitis. Terfenadine and Diclofenac are used as controls, the biscarpamontamine A has exact curative effect and is disclosed for the first time, and as a frame type is a brand-new frame type, having high rhinitis treatment activity, the biscarpamontamine A has excellent substantive features and has significant progress in rhinitis prevention and treatment.

Description

technical field [0001] The invention relates to a new application of the compound Biscarpamontamine A, in particular to an application of the Biscarpamontamine A in preparing a medicine for treating rhinitis. Background technique [0002] Rhinitis is a common and frequently-occurring disease in clinical practice. The occurrence of rhinitis is mainly related to allergic reactions and belongs to the category of immune inflammation. At present, antihistamine drugs such as terfenadine or antiallergic drugs such as tranilast and ketotifen are mainly used for the treatment of rhinitis, and these drugs have poor or ineffective effects on chronicity and recurrent rhinitis. Therefore, small molecular compounds with clear components, quality control, safety and high efficiency have potential value in the development of drugs for rhinitis treatment. [0003] The compound Biscarpamontamine A involved in the present invention is a brand-new compound 9 published in 2009 (Kazumasa Zaima, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/475A61P11/02
CPCA61K31/475A61K9/0053A61K9/2059A61K9/4866
Inventor 田丽华
Owner ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap